Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of Sitagliptin in Combination With Pembrolizumab in Refractory or Relapsed Advanced Renal Cell Carcinoma and Melanoma

NCT07634380 is registered in ClinicalTrials.gov with Fernando Maciel Barbosa as lead sponsor.

NCT NCT07634380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07634380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of Sitagliptin in Combination With Pembrolizumab in Refractory or Relapsed Advanced Renal Cell Carcinoma and Melanoma
Lead sponsor
Fernando Maciel Barbosa
Phase
Phase 1
Overall status
Recruiting
Start date
May 14, 2026
Completion date
April 10, 2031
Enrollment
64 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma, advanced renal cell carcinoma